Cartesian Therapeutics Announces Board Changes and Shareholder Votes
Ticker: RNAC · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1453687
| Field | Detail |
|---|---|
| Company | Cartesian Therapeutics, Inc. (RNAC) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, officer-appointment, director-election, shareholder-vote
TL;DR
Cartesian's board is changing, execs are getting new pay, and shareholders are voting on stuff. Big moves ahead?
AI Summary
Cartesian Therapeutics, Inc. announced on June 14, 2024, a series of significant corporate actions. These include the election of new directors, the appointment of certain officers, and the approval of compensatory arrangements. Additionally, the company submitted matters to a vote of its security holders, indicating potential strategic decisions or changes being put before shareholders.
Why It Matters
Changes in board composition and executive appointments can signal shifts in company strategy or governance, while shareholder votes indicate key decisions are being made that could impact the company's future direction.
Risk Assessment
Risk Level: medium — The filing details changes in corporate governance and executive compensation, which can introduce uncertainty or signal strategic shifts that carry inherent risks.
Key Players & Entities
- Cartesian Therapeutics, Inc. (company) — Registrant
- June 14, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37798 (identifier) — Commission File Number
- 704 Quince Orchard Road, Gaithersburg, MD 20878 (address) — Address of principal executive offices
- 617-923-1400 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Cartesian Therapeutics' security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
Who are the newly elected directors or appointed officers at Cartesian Therapeutics?
The filing states that there was an election of directors and appointment of certain officers, but their names are not specified in this document.
What are the details of the compensatory arrangements for certain officers?
The filing mentions compensatory arrangements for certain officers, but the specifics of these arrangements are not detailed in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 14, 2024.
What is the principal executive office address for Cartesian Therapeutics, Inc.?
The principal executive office address for Cartesian Therapeutics, Inc. is 704 Quince Orchard Road, Gaithersburg, MD 20878.
Filing Stats: 879 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2024-06-17 07:54:40
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind
Filing Documents
- rnac-20240614.htm (8-K) — 40KB
- 0001453687-24-000088.txt ( ) — 165KB
- rnac-20240614.xsd (EX-101.SCH) — 2KB
- rnac-20240614_lab.xml (EX-101.LAB) — 22KB
- rnac-20240614_pre.xml (EX-101.PRE) — 13KB
- rnac-20240614_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 14, 2024, the Company held the Annual Meeting. A total of 13,755,429 shares of the Company's common stock, par value $0.0001 per share (the "common stock"), were present electronically or represented by proxy at the meeting, representing approximately 77.29% of the Company's outstanding common stock as of the April 18, 2024 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Proxy Statement. Proposal 1 - Election of two Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Carrie S. Cox 11,829,626 316,083 1,609,720 Murat Kalayoglu, M.D., Ph.D. 12,106,239 39,470 1,609,720 Based on the votes set forth above, each director nominee was duly elected to serve until the Company's 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. Proposal 2 - Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company's named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 11,684,828 443,703 17,178 1,609,720 Based on the votes set forth above, the stockholders approved on a non-binding and advisory basis, a resolution approving the compensation of our named executive officers. Proposal 3 - Approval of the Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan, which is an amendment and restatement of the Selecta Biosciences, Inc. 2016 Incentive Award Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 11,273,065 856,549 16,095 1,609,720 Based on the votes set forth above, the stockholders approved the Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan. Proposal 4 - Ratificat
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: June 17, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer